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Abstract: The ZAP-70 protein is a member of the Syk/ZAP protein tyrosine kinase family, normally expressed in T cells and
NK cells but not found in normal, mature B cells. The protein plays a critical role in the initiation of T-cell signaling. Leukemic
cells from patients with B-cell chronic lymphocytic leukemia (B-CLL) that expressed nonmutated immunoglobulin V genes
were found to express levels of ZAP-70 protein that were comparable to those detected in T cells of healthy adults. The ZAP-70
protein expression can be evaluated by flow cytometry and may be used as a prognostic marker in B-CLL patients. We modified
the method of immunocytochemical assessment of ZAP-70 expression. The traditional two-step method with monoclonal
anti-ZAP-70 antibody in the first step followed by FITC-conjugated goat anti-mouse IgG was changed for one-step method
with monoclonal anti-ZAP-70 antibody labeled by Zenon Alexa Fluor 488. The method is simple and fast. The major advantage
of Zenon labeling technique is its compatibility with simultaneous staining of surface antigens. The cells may be earlier
immunostained for CD3, CD19 and/or CD5 to compare of the ZAP-70 kinase expression in B and T cells.
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Introduction
The B-cell chronic lymphocytic leukemia (B-CLL) has
variable clinical course. Although the median survival
time of patients with this form of leukemia is around 10
years, in individual patients the prognosis is extremely
variable. Thus, some patients have a long survival with-
out major progression while others have more ag-
gressive disease with progressive clinical features and
require earlier therapy [2, 12]. The prognostic factors
and categories are well defined, starting from the clinical
staging systems [1, 13] which are the classical gui-
delines. Other prognostic factors include the perfor-
mance status, age, pattern of bone marrow involvement,
serum levels of β2-microglobulin and soluble CD23
molecule, P53 expression, somatic mutation of VH im-
munoglobulin genes and different genomic aberrations
[8, 10, 15]. 
There is an intense search for the prognostic markers
that might facilitate the treatment of patients according
to individual prognosis. It appeared in multivariate ana-
lyses that IgVH gene mutational status is a good predictor
of clinical outcome. Patients having B-CLL cells with
nonmutated IgVH genes often have progressive disease
and have poorer prognosis, whereas patients whose
leukemic cells express mutated IgVH regions more often
have a slowly progressing disease [6, 7]. The prognostic
value of the IgVH mutational status is independent of the
clinical stages [2]. However, most clinical diagnostic
laboratories are not prepared to perform routinely se-
quencing of IgVH genes, the analysis is time consuming
and expensive. 
It has been found that the expression of the gene
coding for ZAP-70 protein (zeta-associated protein 70)
is high in B-CLL cells of patients with nonmutated IgVH
genes and low or absent in B-cells of patients with
mutated genes [2, 14, 14]. ZAP-70 is a tyrosine kinase
protein [3] essential for T cell signaling but not found in
normal peripheral blood B cells. Hence, this marker
appears to be a good discriminator between the two
groups of B-CLL patients [2, 4, 14]. 
This study presents a modification of previously
described immunocytochemical method [5] for flow
cytometric examination of ZAP-70 protein expression
Correspondence: A. Bojarska-Junak, Dept. Clinical Immunology,
University School of Medicine, Jaczewskiego 8, 20-950 Lublin,
Poland; e-mail: agnieszkajunak@poczta.onet.pl
in B cells from patients with B-CLL. The modified
procedure is a one-step immunocytochemical method
using monoclonal anti-ZAP-70 antibody conjugated
with labeled Fab fragments of Fc-specific anti-mouse
IgG2a antibody.
Materials and methods
Reagents. Anti-ZAP-70 antibody, clone 2F3.2 (mouse monoclonal
IgG2a) (lot. 24920) was purchased from Biomol Research Labora-
tories and clone 29 mouse IgG2a (cat. 610239) from Pharmingen.
Goat anti-mouse FITC-conjugated IgG (lot. 41868) was provided by
Becton Dickinson. ZenonTM Alexa Fluor® 488 Mouse IgG2a Labe-
ling Kit (lot 75C4-1 and 75C3-1) was obtained from Molecular
Probes. Monoclonal antibodies: anti-CD19 PE, anti-CD3 PE, anti-
CD5 CyChrome and the negative controls were obtained from Caltag
Laboratories. Monoclonal antibody anti-CD19 CyChrome was pur-
chased from Becton-Dickinson. Monoclonal antibody anti-CD3 con-
jugated with magnetic beads was provided by Miltenyi Biotec.
Patients and samples. Peripheral blood samples were obtained from
22 newly diagnosed, untreated patients with B-CLL. The diagnosis
of B-CLL was made on the basis of clinical examination, as well as
morphological and immunological criteria. All peripheral blood
samples were collected in heparinized tubes and immediately pro-
cessed. Mononuclear cells were isolated by density gradient centrifu-
gation on Gradisol L (Aqua Medica, Poland) for 25 min at 400 × g,
at room temperature. The interphase cells were removed and washed
twice in phosphate-buffered saline (PBS) and then resuspended at
1×106 cells per tube for future assays. Peripheral blood from 11
healthy persons was also analyzed. The written consent was obtained
from the patients and healthy volunteers.
Two-step ZAP-70 immunocytochemical reaction using FITC-
conjugated goat anti-mouse IgG. The CD19+ B cells used in this
experiment were purified by negative selection using the magnetic-
activated cell-sorting (MACS) system. They were purified from
patients’ blood mononuclear cells by treatment with the specific
monoclonal antibody (mAb) against T lymphocytes (anti-CD3) con-
jugated with magnetic beads according to the manufacturer’s instruc-
tion. The purification was verified by flow cytometry: B-CLL cells
contained more than 97% of CD19+ lymphocytes. B lymphocytes
from 10 healthy adults were also separated in the same way.
Expression of ZAP-70 in the purified CD19+ cells was measured
by an indirect labeling procedure using FITC-conjugated goat anti-
mouse IgG. Briefly, purified B lymphocytes were fixed with 1%
paraformaldehyde in PBS for 15 min at room temperature. Next, 70%
ethanol was added to permeabilize the cell membranes (1 h at -20˚C).
After fixation and permeabilization, cells were incubated with 0.5
µg, 1 µg or 2 µg of anti-ZAP-70 primary antibody per 106 cells for
30 min at room temperature. Next, the cells were washed with PBS
and then treated with FITC-conjugated goat anti-mouse IgG as a
secondary antibody. Following an additional 30-min incubation at
room temperature, cells were washed with PBS and analyzed by flow
cytometry.
One-step ZAP-70 immunocytochemical reaction using ZenonTM
Alexa Fluor® 488 Mouse IgG2a Labeling Kit. For ZAP-70 immu-
nocytochemical reaction, concentrations of 0.5 µg, 1 µg or 2 µg of
anti-ZAP-70 antibody per 106 cells were tested. The best results were
obtained with 1µg mAb/106 cells, and it was used in further experi-
ments. Five µl of Zenon mouse IgG labeling reagent, which contains
a fluorophore-labeled Fab fragment, were mixed with 1 µg (5 µl) of
the antibody solution. The mixture was incubated for 5 minutes at
room temperature. Then 5 µl of the Zenon blocking reagent was
added to the reaction mixture. The solution was incubated for addi-
tional 5 min and applied to the cell sample.
One hundred µl of peripheral blood mononuclear cells (1×106
cells/ml) were added to a flow cytometry tube and immunostained
with monoclonal antibodies against the cell-surface markers: CD19
PE, CD19 CyChrome, CD5CyChrome or CD3 PE. The cells were
then fixed in 1% paraformaldehyde solution in PBS for 15 min at
room temperature, permeabilized with 70% ethanol for at least 1 h
at -20˚C and washed with PBS. After centrifugation, the supernatant
was discarded. Next, anti-ZAP-70 antibody, labeled using the Zenon
mouse IgG labeling reagent, was added to the sample tubes. The
samples were incubated for 10 or 30 min at room temperature,
washed once with PBS and immediately analyzed by flow cytometry.
The best results were obtained following an incubation for 30 min,
and it was used in further experiments. The cells identified as
CD3-positive cells and CD19-negative lymphocytes (generally T
and NK cells) served as internal positive controls (Fig. 1).
Flow cytometry analysis. Samples were analyzed by flow cyto-
metry using a Becton Dickinson FACSCalibur instrument equipped
with 488-nm argon laser. Five data parameters were acquired and
stored: linear forward and side scatter (FSC, SSC), FL-1(FITC),
FL-2(PE) and FL-3(CyChrome). An acquisition gate was established
based on FSC and SSC that included mononuclear cells and excluded
dead cells and debris. For each analysis, 10 000 events were acquired
and analyzed using CellQuest software. 
Statistical analysis. Nonparametric statistics was used. Median
values as well as 25th percentile (P25) and 75th percentile (P75)
values were calculated. The two-group Mann-Whitney U-test was
used for comparison of the results.
Results
In our first assessment of ZAP-70 protein expression,
we followed description of other authors [3], using two-
step immunocytochemical procedure. The B CD19+
cells from untreated patients (n=18) with B-CLL were
purified by negative selection using specific mAb
against T lymphocytes conjugated with magnetic beads.
More than 97% of the cells in each case expressed CD19.
In these samples assessed with two-step procedure, the
proportion of B cells expressing ZAP-70 was 13.6% to
83.8%. In healthy blood donors (n = 10), the proportion
of B cells expressing ZAP-70 was in the range of 4.3%
to 10.3 %. Median value was 7.1%, P25-P75 = 6.3-8.4%.
Then we tested the modified, one-step immunocyto-
chemical procedure with the peripheral blood mononu-
clear cells to assess ZAP-70 protein expression. In this
technique, fluorochrome-labeled antibodies against cell
surface markers were also used. The sequence of ana-
lysis for identification of CD19+/CD5+ leukemic cells
and CD3 T cells expressing ZAP-70, following three or
two-color labeling is presented in Figure 1. The percent-
age of ZAP-70+/CD19+/CD5+ cells in untreated pa-
tients (n = 22) was in the range of 2.4-83.7%. As
observed by Crespo et al. [5], in patients in whom 20%
or more of the leukemic cells are positive for ZAP-70,
IgVH is nonmutated, whereas IgVH mutations are found
in patients in whom less than 20% of the leukemic cells
are positive for ZAP-70. Assuming this cut-off value, 12
patients tested with the modified method had ZAP-70-
positive CD19+/CD5+ leukemia cells in the lower range
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(2.4-19.1%, median value 10.7%, P25-P75 = 7.1-
14.8%). The other ten patients had ZAP-70-positive
leukemia cells in the higher range (20.5-83.7%, median
value 47.4%, P25-P75 = 27.3-49.0%). In all samples,
ZAP-70 was positive in CD3+ T cells, which were
considered as the internal standard. 
In samples from healthy volunteers, the proportion
of B cells (CD19+) expressing ZAP-70 was 0.3% to
5.6%, median value 3.7%, P25-P75 = 1.0-2.0%. These
results are in accordance with findings of other authors
[5, 11]. The percentage of ZAP-70-positive B lympho-
cytes for healthy persons when tested with both de-
scribed procedures are significantly different
(p=0.0003), what suggests that the preparation of the
cells and the immunocytochemical procedure influence
the results. Figure 2 shows ZAP-70 protein expression
by B CD19+ and T CD3+ cells from healthy person.
The monoclonal anti-ZAP-70 antibody of clone 29
from Pharmingen labeled with Zenon and tested with the
one-step procedure was found to nonspecifically bind to
peripheral blood B lymphocytes (CD19+) of healthy
persons as well as of patients. Therefore, data presented
above included only results of flow cytometric analysis
of samples labeled by anti-ZAP-70 antibody purchased
Fig. 1. The dot plots show representative data from one B-CLL patient, illustrating the method for identification of CD19+/CD5+ leukemic
cells and CD3+ T-cells expressing ZAP-70 following three- or two-color staining. ZAP-70 antibody was labeled using Zenon technique. An
acquisition gate was established based on FSC and SSC that included mononuclear cells. Region R1 was drawn around the lymphocytes (a).
Next, the R1 gated events were analyzed for CD19+PE/CD5+CyChrome or CD3 PE staining and positive cells (CD19+/CD5+ or CD3+)
were selected (region R2) (b, c). We used dot plots of CD19 PE versus CD5 CyChrome (b) or SSC versus CD3 PE (c). The final dot plots:
CD19 PE vs ZAP-70 (d) and CD3 PE vs ZAP-70 (e) were established by combined gating of events using R1 and R2. The numbers in the
upper right quadrant on the dot plots d, e represent the percentage of CD19+/CD5+/ZAP-70+ and CD3+/ZAP-70+ cells. The dot plot f shows
ZAP-70 expression after all lymphocyte gating (R1). Lower right quadrant shows ZAP-70 expression by CD19- lymphocytes (generally T
and NK cells), which provided a useful positive control for antibody activity.
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from Biomol Research Laboratories. The antibody of the
clone 29 was previously used for immunoprecipitation
or Western blot analyses only [4].
Discussion
ZAP-70 expression is an unusual finding in chronic
lymphocytic leukemia B-cells, since the protein has
not been reported in normal circulating B cells. Recent
studies have shown that expression of the protein
tyrosine kinase ZAP-70 may serve as a prognostic
marker in B-CLL which will eventually predict survi-
val of the patients [2, 5]. The analysis of B-CLL cells
suggests that the IgVH gene mutation status is stably
coexpressed with ZAP-70 protein [2], while expression
of another marker - CD38 antigen may change in the
course of the disease [6]. Moreover, the study of Crespo
et al. [5], who used the same clone (2F3.2) anti-ZAP-70
antibody as that used in the present study, showed that
the leukemic cells without IgVH mutations express at
least 20% ZAP-70-positive cells. In our experiments, we
observed expression of ZAP-70 protein in a small sub-
population of peripheral blood B lymphocytes of healthy
volunteers. A significantly lower median value of this
subpopulation was observed after the modified proce-
dure as compared with the double-step method, possibly
due to the nonspecific, higher background in the latter.
These differences, however should not influence the
clinical prognostic result in most patients, specially
since some authors propose 15% ZAP-70-positive cells
as the cut-off value [11]. The leukemic cells of patients
with IgVH mutations have barely detectable levels of
ZAP-70. On the other hand, in the immunoblot analyses
of Chen et al. [4], B-CLL cells with nonmutated immu-
noglobulin V genes were found to express levels of
ZAP-70 protein that were comparable to those de-
tected in the peripheral blood T-cells of healthy adults.
In our pilot study [9], an increased percentage of
ZAP-70-positive leukemic cells was associated with
short time to progression, lymphocyte count and dis-
ease risk status. Moreover, the majority of ZAP-70-ne-
gative leukemia cells were observed in patients with
stable disease.
In our assessment of ZAP-70 protein expression, two
different approaches were used to determine the best
method of detecting purified anti-ZAP-70 monoclonal
antibody (IgG2a): FITC-conjugated goat anti-mouse IgG
and Zenon Mouse IgG labeling procedure. In general,
both methods may be used to identify ZAP-70 express-
ion, however each method has its advantages and limi-
tations. In our opinion, Zenon Mouse IgG labeling
procedure is simple and gives reproducible results, as
required for clinical procedures. This technology is de-
signed for use with a particular mouse monoclonal anti-
body isotype (IgG2a) and may be applied in other
immunocytochemical procedures as well. For assess-
ment of cell-surface phenotype, mouse antibodies of
other isotype (IgG1) may be used. In the procedure,
individual cells can be sequentially analyzed for the
expression of surface markers and intracellular ZAP-70
protein. 
In summary, the Zenon labeling of ZAP-70 antibody
used in the immunocytochemical method produces less
nonspecific background than the two-step procedure
with FITC-conjugated goat anti-mouse IgG. The modi-
fied assay is easy to perform, does not require purifica-
tion of the B cells, and may be suggested to become an
established clinical prognostic test available to all B-
CLL patients.
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